Husmetabo 2,5 mg Injektionsvätska, lösning i förfylld spruta

Država: Švedska

Jezik: švedski

Izvor: Läkemedelsverket (Medical Products Agency)

Preuzimanje Uputa o lijeku (PIL)
19-07-2018
Preuzimanje Svojstava lijeka (SPC)
28-04-2018

Aktivni sastojci:

metotrexat

Dostupno od:

Sigillata Limited

ATC koda:

L04AX03

INN (International ime):

methotrexate

Doziranje:

2,5 mg

Farmaceutski oblik:

Injektionsvätska, lösning i förfylld spruta

Sastav:

metotrexat 2,5 mg Aktiv substans

Razred:

Apotek

Tip recepta:

Receptbelagt

Područje terapije:

Metotrexat

Proizvod sažetak:

Förpacknings: Förfylld spruta, 4 x 1 st (med fast injektionsnål) (med automatiskt nålskydd och spritsudd); Förfylld spruta, 1 st (med fast injektionsnål) (med automatiskt nålskydd och spritsudd); Förfylld spruta, 1 st (med fast injektionsnål) (med automatiskt nålskydd); Förfylld spruta, 1 st (med fast injektionsnål) (med spritsudd); Förfylld spruta, 1 st (med fast injektionsnål); Förfylld spruta, 4 x 1 st (med fast injektionsnål) (med automatiskt nålskydd); Förfylld spruta, 4 x 1 st (med fast injektionsnål) (med spritsudd); Förfylld spruta, 4 x 1 st (med fast injektionsnål); Förfylld spruta, 12 x 1 st (med fast injektionsnål); Förfylld spruta, 12 x 1 st (med fast injektionsnål) (med automatiskt nålskydd och spritsudd); Förfylld spruta, 12 x 1 st (med fast injektionsnål) (med automatiskt nålskydd); Förfylld spruta, 12 x 1 st (med fast injektionsnål) (med spritsudd)

Status autorizacije:

Avregistrerad

Datum autorizacije:

2015-09-24

Uputa o lijeku

                                1
PACKAGE LEAFLET: INFORMATION FOR THE USER
HUSMETABO 2.5 MG, 7.5 MG, 10 MG, 12.5 MG, 15 MG, 17.5 MG, 20 MG, 22.5
MG, 25 MG, 27.5 MG AND
30 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
methotrexate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Husmetabo is and what it is used for
2.
What you need to know before you use Husmetabo
3.
How to use Husmetabo
4.
Possible side effects
5.
How to store Husmetabo
6.
Contents of the pack and other information
1.
WHAT HUSMETABO IS AND WHAT IT IS USED FOR
Husmetabo contains methotrexate as active substance.
Methotrexate is a substance with the following properties:
-
it interferes with the growth of certain cells in the body that
reproduce quickly
-
it reduces the activity of the immune system (the body’s own defence
mechanism)
-
it has anti-inflammatory effects.
Husmetabo is indicated for the treatment of
-
active rheumatoid arthritis in adult patients.
-
polyarthritic forms of severe, active juvenile idiopathic arthritis,
when the response to
nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate.
-
severe recalcitrant disabling psoriasis, which is not adequately
responsive to other forms of
therapy such as phototherapy, PUVA, and retinoids, and severe
psoriatic arthritis in adult
patients.
-
mild to moderate Crohn’s disease in adult patients when adequate
treatment with other
medicines is not possible.
Rheumatoid arthritis (RA)
is a chronic collagen disease, characterised by inflammation of the
synovial membranes (joint membranes). These
                                
                                Pročitajte cijeli dokument
                                
                            

Svojstava lijeka

                                MARKNADSFÖRS EJ FÖR NÄRVARANDE.
_Produktinformation_
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Uputa o lijeku Uputa o lijeku engleski 14-04-2021
Svojstava lijeka Svojstava lijeka engleski 28-09-2020
Izvješće o ocjeni javnog Izvješće o ocjeni javnog engleski 24-09-2015